Ascendis Pharma A/S (ASND) Research

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.

Market snapshot

Symbol
ASND
Price
$230.83
Day change
-0.14%
Market cap
$12.5B
P/E ratio
24.52x
52-week range
160.86-250.74
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$287.5

Peer companies

  • BridgeBio Pharma, Inc. (BBIO)
  • BioMarin Pharmaceutical Inc. (BMRN)
  • Exelixis, Inc. (EXEL)
  • Guardant Health, Inc. (GH)
  • Ionis Pharmaceuticals, Inc. (IONS)
  • Madrigal Pharmaceuticals, Inc. (MDGL)
  • Moderna, Inc. (MRNA)
  • Roivant Sciences Ltd. (ROIV)

Recent insider activity

  • SMITH SCOTT THOMAS — P-Purchase (100 shares) on 2026-06-02
  • BIENAIME JEAN JACQUES — P-Purchase (100 shares) on 2026-05-29
  • BIENAIME JEAN JACQUES — P-Purchase (200 shares) on 2026-05-29
  • BIENAIME JEAN JACQUES — P-Purchase (200 shares) on 2026-05-29
  • SMITH SCOTT THOMAS — P-Purchase (250 shares) on 2026-05-29

Open Ascendis Pharma A/S (ASND) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.